Introduction: Psoriasis is a chronic skin disorder associated with several
. In obese psoriatic patients, an energy-restricted diet designed to increase n-3 and to reduce n-6 polyunsaturated fatty acids (PUFAs), ameliorated the metabolic profile and, by increasing the response to immuno-modulating therapy, improved the clinical outcomes of the disease [18] . Moreover, metabolic syndrome is characterized by a state of chronic systemic inflammation sustained by the adipose tissue, that is not a mere inert fat storage but an endocrine organ secreting multiple mediators, named "adipokines", contributing to inflammation, as well as to glucose and lipid metabolism, and endothelial cell function regulation [19] . Traditionally, two types of adipose tissue are recognized: brown adipose tissue (BAT), associated with energy expenditure as well as thermogenesis and white adipose tissue (WAT), responsible for energy storage [20] . In addition to adipocytes, adipose tissue also contains endothelial cells, fibroblasts, macrophages, myeloid cells and T cells [21] . In a lean state, T helper (h)2 cells, T regulatory (reg), Breg, and invariant natural killer (NK)T cells are the dominant cell population in WAT [22, 23] ; in contrast, augmented adiposity results in increased number of pro-inflammatory immune cells, including Th1 and Th17 cells [22, 24] . Adipokines are able to orchestrate the interaction between metabolic and immune systems. The wide array of adipokines, secreted by the adipose tissue, includes at least 50 bioactive molecules [25] , not all exclusively produced by adipocytes. In particular, resident macrophages contribute to the production of some cytokines and chemokines such as (Table 1) [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Notably, TNF-α is highly expressed in both psoriasis and obesity [46] , and similarly, other adipokines (i.e., IL-6 and leptin) are known as proinflammatory mediators and may contribute to psoriasis inflammation [3] . Meanwhile, the same pro-inflammatory mediators (i.e., TNF-α and IL-6) may (i) impair glucose metabolism, inducing insulin resistance, or they may lead to (ii) endothelial dysfunction, (iii) altered lipid metabolism, (iv) hypertension, and (v) enhanced risk of cardiovascular diseases [46] . However, in a context of chronic adipose tissue inflammation, characterizing obesity, associated or not with insulin resistance, also the adaptive immunity is indeed and CD8+ T cells in adipose tissue, conversely to lean mice, predominantly characterized by a Th2-and Treg-oriented immune activation [50] . Furthermore, diet-induced obese mice and obese human subjects showed elevated IL-6 levels, which predispose to the Th17 lineage expansion, resulting in an increased number of IL-17-secreting CD4+ cells [24] . As mentioned above, psoriasis increases the risk of developing obesity but, concurrently, obesity has been associated with an increased prevalence and severity of psoriasis, even in pediatric population [6, 51, 52] . The fact that obesity may aggravate psoriasis severity has been also confirmed by obese mice model developing exacerbated psoriasis-like lesions after imiquimod induction [53] . In this model, obesity worsened skin lesions enhancing the expression of key-cytokines and their   downstream gene products, particularly IL-17A, IL-22, IL-23p19, IL-17C, and β-defensin 3 [53] . Additionally, obesity may negatively affect clinical response to systemic antipsoriatic treatment, and, conversely, weight loss improves psoriasis as well as the therapeutic response [54] [55] [56] .
Albeit some evidence suggested the potential role of pro-inflammatory psoriasissignature cytokines in obesity pathogenesis, and, similarly, the role of adipokines in psoriasis pathogenesis, the mechanisms linking psoriasis and obesity, and more in general metabolic syndrome, are not fully investigated. For instance, the association between psoriasis and adipokines is reported, though evidence associating psoriasis or disease severity with altered circulating adipokine levels is controversial. Takahashi et al. detected a significant negative correlation between plasma adiponectin levels and PASI score, whereas plasma leptin levels were enhanced with increasing PASI score, though not statistically significant [57] . Along these lines, TNF-α plasma concentration negatively and significantly correlated with plasma adiponectin levels, whereas plasma leptin levels were not correlated [57] . Conversely, in another study, both serum adiponectin and leptin levels were significantly decreased in psoriatic patients in comparison with the control group [58] . Other reports detected significantly lower levels of adiponectin and visfatin, and significantly higher levels of vaspin, omentin, chemerin, and resistin in psoriatic patients as compared to the control group [42, [59] [60] [61] [62] . Of note, a meta-analysis including nine case-control studies, containing 421 psoriasis patients and 348 healthy controls, revealed a statistically significant association between serum resistin levels and psoriasis [59] . Interestingly, successful treatment of psoriasis with biologicals (i.e., infliximab and ustekinumab) or phototherapy (narrow band-UVB) was related to an increase of adiponectin serum levels and a decrease of leptin and resistin serum concentration [60] . Coban et al. observed higher levels of chemerin in patients than in controls and a strongly positive correlation between the PASI score and chemerin [61] . Moreover, psoriatic patients showing an improvement in the PASI score correlating with a significant decrease in serum leptin, omentin, and chemerin values, and a significant increase of serum adiponectin levels [61] .
Conversely, Gisondi et al. found a significant decrease in the PASI score and serum chemerin levels, but no correlation was identified between these two
Overall, a general agreement regarding the circulating adipokine levels and their pathogenic relevance in psoriasis patients needs to be defined.
Thus, this review is aimed to provide an updated "state-of-the-art" about the reciprocal contribution of a small subset of conventional cytokines and adipokines involved in chronic inflammatory pathways, upregulated in both psoriasis and increased adiposity. The main effects of psoriasis-signature cytokines on increased adiposity as well as of adipokines on psoriasis pathogenesis have been summarized in Table 2 . According to the current pathogenic model , we selected the most pathogenically relevant cytokines. IL-17 is recognized as the key cytokine in psoriasis [63] . Overall, IL-17A is not proved to profoundly impact on obesity and metabolic status, as suggested by the no-protection from metabolic syndrome and noimprovement of adipose tissue metabolism in established obesity occurring in IL-17KO mice [40] . Nevertheless, IL-17 maintains its pro-inflammatory effects inducing adipocyte production of inflammatory mediators including IL-6, whose expression in adipocytes is regulated by an IL-17 signature transcription factor, C/EBP-β.
IL-22
Although adipose tissue is known to express the membrane receptor Because IL-1β release is stimulated by IL-22, and IL-1β represents a key inducer of Th17 differentiation, a feed-forward circuit between IL-1β-producing macrophages and Th17 cells might be established [66] .
TNF-α
Physiologically, TNF-α constitutes a restraining cytokine involved in the complex mechanisms of adipose tissue metabolism. Accumulating macrophages in adipose tissue are considered the most relevant source of TNF-α, and other proinflammatory molecules and their infiltration positively correlated with increased adiposity [67] . TNF-α stimulates adipocyte leptin synthesis [68] , induces lipolysis and inhibits both lipogenesis and anabolic insulin-like growth factor 1 (IGF-1) production [43, 69] . Thus, TNF-α could presumably have a protective role against obesity, with mechanisms limiting body mass increase.
This evidence may, at least partially, give reason of (i) the enhanced TNF-α levels detected in obese subjects, with putative protective function; (ii) the body weight increase observed in psoriatic patients undergoing treatment with TNF-α inhibitors or other antipsoriatic agents decreasing TNF-α expression levels [56, [70] [71] [72] . However, data on TNF-α role in increased adiposity are controversial as it may also contribute to obesity counteracting insulin receptor activity and inhibiting glucose transporter (GLUT)-4, with a consequent enhancement of insulin levels that stimulates the hunger center [68] . Notwithstanding mounting evidence suggesting the TNF-α contribution to insulin resistance, anti-TNF-α-binding protein administration failed to improve insulin resistance in diabetic or insulin-resistant patients [73] . Likewise, anti-TNF-α therapies in non-diabetic psoriatic patients did not significantly vary serum concentrations of both leptin and resistin [74] . Overall, the ability of TNF-α blockade in dampening both resistin and leptin levels is still debated and controversial, albeit the antiinflammatory effect of anti-TNF agents is more likely associated with an increased body weight, positively correlating with leptin serum levels, and a presumable reduction of insulin resistance.
IL-6
This adipo-cytokine is produced by a plethora of both immune and tissue cells that includes macrophages, dendritic cells, T cells, B cells, keratinocytes, fibroblasts, endothelial cells, and adipocytes. Particularly, it is increasingly expressed in inflammatory conditions such as psoriasis, in metabolic conditions such as obesity-associated insulin resistance [75, 76] . In obesity setting, IL-6 expression mainly derives from adipose tissue, particularly from adipocytes and adipose tissue-derived macrophages, contributing 33% and 20%, respectively [67] . In a recent study, adipose tissue-dendritic cells were also demonstrated to express higher levels of IL-6, as well as IL-23 and TGF-β [77] .
IL-6 has pleiotropic effects acting on a variety of cells. With regard to obesity, lipolysis process, and insulin resistance, its role is still debated. Nevertheless it is reported to (i) suppress lipoprotein lipase activity; (ii) to stimulate energy expenditure; (iii) to show anorexic effects suppressing appetite [78] . Because of its neuroendocrine activity it affects the central nervous system (i) regulating the hypothalamus-pituitary-adrenal axis, thus modulating cortisol release; (ii) stimulating liver secretion of acute-phase proteins; (iii) affecting steroid hormone conversion, altering sex hormone balance and therefore adipose tissue distribution [78, 79] .
In a mice model, IL-6 stimulation was demonstrated to interfere with insulin signaling in hepatocytes, favoring insulin resistance [80] . In contrast, IL-6 deficiency was associated with obesity and hepatic inflammation, whereas IL-6 administration reverted insulin resistance [81] . The contrasting data on lipid and glucose metabolism suggest that IL-6 effects may be dependent on its tissuespecific activity and on the localization of its increased expression [82] .
Beside its activity in regulating insulin resistance and obesity, IL-6 is also crucial for linking these metabolic disorders to inflammation. A diet-induced obese model showed an increased number of IL-17-secreting CD4+ T cells, whose development was dependent on IL-6 stimulation [24]. Indeed, IL-6 KO mice on high-fat diet, despite developing obesity, did not show a Th17-skewed differentiation, indicating that obesity-induced Th17 differentiation was IL-6-dependent [24] . Notably, adipose tissue contributes to IL-17-producing T cell development, through adipose-tissue dendritic cell-derived products (i.e., IL-23, TGF-β, and IL-6) that are involved in IL-17-producing T cell differentiation and expansion [77] .
Role of adipokines in psoriasis inflammatory pathway

Leptin
Compared to the multitude of studies on systemic leptin effects, its role in the skin is poorly investigated. Leptin is mainly secreted by adipocytes and directed to target cells, such as epithelial cells, nervous cells and immune cells expressing its receptor LepR [27, 83] . Indeed, leptin is known to stimulate keratinocyte proliferation in vitro and to act as a mitogen during skin repair in vivo [84] . In accordance, LepR is particularly expressed in proliferating basal layer and in neo-epithelial keratinocytes during skin repair [84] . It have been shown activation of the classical leptin pathway via JAK/STAT cascade in human HaCaT cells during wound repair, and induction of keratinocyte-derived proinflammatory cytokines, such as IL-6, IL-8 and TNF-α [85] . In addition, leptin is able to alter keratinocytes redox state increasing ROS generation as well as the ratio of oxidized/reduced glutathione, and AP-1 activity [86] . This could be linked to the effects of leptin in the psoriatic inflammatory cascade, although findings are controversial. Johnston et al. reported that leptin mRNA levels in involved and uninvolved psoriatic skin were similar to healthy controls [87] .
However, in following studies leptin resulted highly represented in psoriatic skin, either in the epidermis, or in the dermis (sweat glands and hair follicles included) [85, 88] . The authors suggested that, although leptin is involved in wound healing, the strong expression in psoriatic skin respect to controls might be due to an enhanced epidermal turnover. Conversely, multiple leptin systemic effects are well recognized: first of all, its pivotal role in body weight regulation by promoting satiety, and energy consumption [89] . Serum leptin variation represents a response to WAT mass increase, and leptin-deficient mice (ob/ob) are severely obese [90] . Leptin is not just a metabolic hormone, since it acts as a mediator with pleiotropic effects [27] . Indeed, as reported in obese mice, leptin increase is also related to several abnormalities regarding: reproduction, hematopoiesis, angiogenesis, bone homeostasis, lipid and glucose metabolism, as well as innate and adaptive immunity [90] [91] [92] . Regarding the innate immunity leptin is able to (i) induce the release of pro-inflammatory mediators (eg. IL-1, IL-6 and TNF-α) by monocytes/macrophages; (ii) enhance production of reactive oxygen species (ROS) by neutrophils; (iii) augment NK cell cytotoxicity.
Moreover, leptin increases macrophage phagocytosis, neutrophil recruitment, NK cell activation, and promotes DC survival [27], participating to the antimicrobial host defense. In the context of adaptive immunity, leptin is involved in T cell generation, maturation and survival [93] . It mediates Th1 phenotype differentiation by increasing IFN-γ, TNF-α and IL-2 production, while it inhibits rapamycin-induced Treg cells, by increasing activation of mammalian target of rapamycin (mTOR), which is up-regulated in psoriatic skin as well as in others inflammatory skin conditions (allergic contact dermatitis and atopic dermatitis) [90, 94] . Moreover, leptin promotes CD4+ cell differentiation into Th17 cells and augments IL-17A production [95] . On the other way, IL-17A also up-regulates leptin release by adipocytes, and the anti-leptin antibody treatment partially antagonizes IL-17A dependent adipogenesis inhibition [96] .
Nonetheless, in the context of severe inflammation, leptin may also exert immune-suppressive functions, decreasing Th1 cytokine expression and reducing T cell proliferation [27] . This suggests that the effects of leptin on the immune system may be dependent on the specific milieu.
Visfatin
It was originally called pre-B cell colony-enhancing factor (PBEF) for its capability to augment pre-B-cell colony formation. Only in the last decade, visfatin has been identified as an adipokine, produced principally by adipocytes and working as a bridge between adipose tissue and inflammatory mediators [97] . Visfatin up-regulates human monocytes and endothelial cells production of several mediators, either pro-inflammatory (e.i. IL-6, TNF-α and IL-1β) or antiinflammatory such as IL-10, IL-1 receptor antagonist (IL-1RA) [97] [98] . It acts as chemoattractant for monocytes and lymphocytes. It is able to induce the expression of co-stimulatory molecules, CD80, CD40, and ICAM-1, on monocytes in order to increase T cell activation through a p38 and MEK mediated pathway [99] . Moreover, visfatin inhibits neutrophil apoptosis by caspase-3 as well as caspase-8-dependend mechanism [97] . All these data demonstrate that this adipokine has a prevalently pro-inflammatory function, further reported also in human keratinocytes. Indeed, it has been demonstrated that visfatin, in combination with TNF-α, stimulates keratinocytes to produce several chemokines (CXCL8, CXCL10, and CCL20), through NF-kB and STAT3 pathway [100] , and antimicrobial peptides (CAMP, hBD-2, hBD-3, and S100A7) [101] . This has also been observed in murine models of psoriasis (imiquimod-treated skin), where antimicrobial peptides were enhanced by visfatin [101] . Increased visfatin serum levels in psoriatic patients and positive correlation with Psoriasis Area Severity Index (PASI) have been reported [102] , reflecting inflammatory state of these patients.
Chemerin
Chemerin is mostly expressed by fat tissue and liver [103] , but also by epithelial barriers, including skin [104] [105] [106] . It is released as inactive precursor and converted in its active form by proteinases [107, 108] , in order to work as ligand for G protein-associated receptor chemokine-like receptor 1 (CMKLR1) [109] .
Chemerin presents a biphasic distribution in normal skin, being over-expressed in the epidermis and down-regulated in the dermis [104, 105] . The real function of chemerin in the skin is not fully clear, but it has been reported to act as antimicrobial protein [104, 106] . Apparently, chemerin mainly works as chemoattractant for CMKLR1+ plasmacytoid dendritic cells (pDCs), macrophages and NK cells, promoting their recruitment at site of tissue damage, and amplifying immune response [107] . Indeed, bacteria and acute phase cytokines, as well as oncostatin M and IL-1β, up-regulate its production, while IL-17 and IL-22 decrease it [110] . On the other hand, chemerin is induced by TNF-α and IL-1β, and its serum levels correlate with TNF-α, IL-6, and C reactive protein [111] , suggesting that it might also act as a mediator of systemic inflammation. Indeed, it has been reported high chemerin circulating levels in psoriasis and psoriatic arthritis patients, with decrease after infliximab therapy [42] . Moreover, uninvolved and involved psoriatic skin contains higher levels of chemerin than normal skin [112] . Accordingly, proteinases required for its activation are overexpressed in involved psoriatic skin [112] . Chemerin is certainly considered as a pro-inflammatory adipokine, but its role in skin diseases needs deeper investigation.
Adiponectin
Adiponectin is highly expressed by mature adipocytes, but also released by skeletal muscle cells, cardiac myocytes, and endothelial cells [30] . Adiponectin, with its multiple oligomeric forms, trimer (LMW), hexamer (MMW), and the
high-molecular weight (HMW) [30], (i) regulates energy homeostasis, (ii)
reduces insulin resistance and (iii) shows anti-atherogenic, anti-angiogenic, and anti-inflammatory functions [113] .
The effect of adiponectin on keratinocytes is yet not fully understood. It has been reported that it inhibits both proliferation and differentiation of keratinocytes. It also suppresses involucrin, TGFβ-2 and -3 expression, and decreases IL-6, IL-8, IL-17, IL-22, and TNF-α secretion by human keratinocytes. In psoriatic patients adiponectin circulating levels are decreased, compared to controls; moreover, they negatively correlated with PASI and the expression of pro-inflammatory mediators, such as IL-6 and TNF-α [114, 115] . The expression of its receptor ADIPOR1 in psoriatic epidermis is also decreased respect to non lesional or healthy skin [116] . Adiponectin influences skin homeostasis also exerting indirect anti-inflammatory effects: (i) inhibiting TNF-α induced adhesion molecule expression; (ii) interfering with macrophage functions; (iii) inducing IL-10 and IL-1RA by human monocytes, macrophages as well as DCs, and (iv) suppressing the production of IFN-γ by lipopolysaccharide (LPS)-stimulated human macrophages [113] . In addition, it reduces T-cell proliferation, macrophage phagocytic capability and macrophage TNF-α production [113] .
Moreover, adiponectin acts as negative regulator on NK cells, suppressing their IL-2-augmented cytotoxic activity [117] . However, several studies have demonstrated that adiponectin also has pro-inflammatory effects, increasing the production of pro-inflammatory factors such as MMP-3, MMP-9, CCL-2, IL-8, and IL-6 [118] [119] [120] . It has been hyphotized that this dual function of adiponectin is isoform-specific: indeed, HWM adiponectin increases IL-6 production in human monocytes, whereas MMW isoform decreases LPS-mediated IL-6 secretion and also induces IL-10 release [121] . Moreover, Jung et al. suggested that adiponectin immunoregulatory ability works activating DCs to release pro-inflammatory cytokines that polarize naïve CD4+ T cells into Th1 and Th17 phenotypes [122] .
Adiponectin enhances IL-17 expression more than IFN-γ, indicating that predominantly induce a Th17 response [123] . The complexity of this adipokine and its involvement in inflammatory skin diseases need to be elucidated.
Conclusion
The relationship between increased adiposity and psoriasis is an interesting as well as a challenging topic. The low but chronic grade of inflammation associated to increased adiposity might be involved in the development or in the amplification of chronic dermatoses, either through a direct interaction between adipocytes and keratinocytes or through the indirect modulation of the adaptive immune system. Adipokines are considered specific biomarkers of inflammation related to increased adiposity, and they might work as a bridge between fat and skin in psoriasis patients (Figure 1 ) [124] . Indeed, in these patients, an excess of adipose tissue augments cardiovascular risk and might compromise the therapeutic response [123, 125] . On the other hand, psoriasis-signature proinflammatory cytokines may alter lipid metabolism, enhancing the risk of increased adiposity and cardiovascular diseases. However, as emerged from the contradictor data analyzed, the mechanism, the temporal link or the biological value of this "pro-inflammatory" connection between inflamed skin and increased adiposity require indeed further investigations.
Expert commentary
Obesity has become a worldwide epidemic health problem, that has taken significant attention to research aimed at understanding the biology of adipocytes and the events occurring in adipose tissue. Several studies show that increased adiposity causes chronic low-grade inflammation that promotes systemic metabolic dysfunction and obesity-linked disorders, such as insulin resistance, type 2 diabetes, atherosclerosis and ischemic heart disease. All these conditions not only reduce life expectancy, but also have enormous economic and societal impact. Increasing epidemiological findings suggests that patients with psoriasis have higher prevalence and incidence of obesity respect to the general population. Better understanding the relationship between psoriasis and increased adiposity is also important for delineating risk factors for all obesitylinked disorders in these patients. It will therefore help to improve future clinical studies that will include adequate adjustments for the presence of obesity as comorbidity among psoriatic patients. Recommendations to reduce weight in obese patients with psoriasis may have favorable effects on obesityassociated disorders as well as on psoriasis severity. Moreover, new therapeutic strategies that balance pro-and anti-inflammatory adipokines levels in obese psoriatic patients could have a beneficial role in preventing and/or treating obesity-related metabolic and cardiovascular comorbidities.
Five-year view
Future studies are necessary to better clarify the mechanisms underlying the relation between increased adiposity and psoriasis. Keratinocytes as well as adipocytes are endocrine organ secreting multiple mediators: cytokines and adipokines, respectively. These represent key actors of the chronic inflammatory process involved both in psoriasis and obesity. The role of TNF-α is well known in psoriasis as well as in obesity pathogenesis and several studies have reported the beneficial effects of the anti-TNF-α treatment on psoriasis comorbidity, such as metabolic syndrome. On the contrary, while the role of IL-17 in psoriasis has been elucidated, controversial are the studies reported in the literature on its role in increased adiposity and adipose tissue homeostasis. Then, we suppose that this point will be more investigated in the next studies, focusing mainly on the impact on psoriasis comorbidity of new biologic anti-IL-17 therapies.
0 Key issues
 Psoriasis is chronic skin disorder associated with several comorbid conditions, including metabolic syndrome.
 The crosstalk between adipose tissue-derived products and psoriasissignature cytokines may contribute to the pathogenesis of both psoriasis and metabolic syndrome. 
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